Related Experiment Videos
Aspergillus spondylodiscitis: successful conservative treatment in 9 cases
B Cortet1, R Richard, X Deprez
1Department of Rheumatology, Centre André Verhaeghe, Centre Hospitalier Régional et Universitaire de Lille, France.
The Journal of Rheumatology
|July 1, 1994
Summary
Medical treatment for aspergillus spondylodiscitis, particularly with itraconazole, proved effective in 9 patients. Early recognition and treatment in immunocompromised individuals are crucial for successful outcomes.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Spinal Infections
Background:
- Aspergillus spondylodiscitis is a rare but serious infection affecting the spine.
- Immunocompromised patients, including organ transplant recipients and those with hematological malignancies, are at higher risk.
Purpose of the Study:
- To evaluate the efficacy of medical treatment for Aspergillus spondylodiscitis.
- To analyze clinical, radiological, and biological outcomes in affected patients.
Main Methods:
- Retrospective analysis of 9 patients diagnosed with Aspergillus spondylodiscitis.
- Diagnosis confirmed by percutaneous needle biopsy and fungal culture (Aspergillus fumigatus or flavus).
- Treatment involved itraconazole, often in combination with flucytosine and/or amphotericin B.
Main Results:
- All 9 patients showed improvement with medical treatment alone, achieving full recovery.
- No surgical debridement was required for any patient.
- Mean treatment duration was 5.5 months, with a mean follow-up of 16 months.
Conclusions:
- Early diagnosis and medical management, particularly with itraconazole, are effective for Aspergillus spondylodiscitis.
- The incidence of this infection may rise due to increasing immunosuppression in various medical conditions.
- Prompt recognition in immunocompromised hosts is vital for successful treatment outcomes.